Long-term ADT Use Can Diminish Tumors’ Visibility on Scans, Study Reports

Long-term ADT Use Can Diminish Tumors’ Visibility on Scans, Study Reports
Long-term use of androgen deprivation therapy (ADT) can make prostate cancer lesions difficult or impossible to see on some imaging scans, even in tumors that continue to grow, a new study shows. Its scientists recommended that patients with aggressive cancer undergo scans before starting with ADT. The study, “Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer," was published in the European Journal of Nuclear Medicine and Molecular Imaging. Imaging of recurrent prostate cancer with conventional techniques such as computed tomography (CT) or magnetic resonance imaging has long been a challenge. In 2011, researchers developed a technique known as 68Ga-PSMA-11 PET/CT that targeted the prostate-specific membrane antigen (PSMA) – a protein that is overexpressed in most aggressive prostate cancers. That technique allowed physicians to scan for recurrent cancer. Men with hormone-sensitive prostate cancer often undergo ADT, which led physicians to question how ADT affects PSMA imaging. Studies have shown that short-term ADT can increase PSMA expression in castration-sensitive prostate cancer cells, leading to greater sensitivity of the imaging technique. But the long-term effects of ADT on PSMA expression and tumor visibility have not been investigated in detail. So researchers did a study to analyze long-term ADT's effect on tumor visibility and detection using PSMA PET/CT scans. The retrospective stud
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *